Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy (Rituximab, Ifosfamide, Carboplatin, and Etoposide) With and Without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-Line Treatment of Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Next Previous
X
Search
Trial Profile

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy (Rituximab, Ifosfamide, Carboplatin, and Etoposide) With and Without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-Line Treatment of Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dacetuzumab (Primary) ; Carboplatin; Etoposide; Ifosfamide; Rituximab
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms MARINER
  • Sponsors Seagen

    • Most Recent Events

    • 05 Oct 2021 This trial has been completed in Spain and France (End Date: 05 May 2011), according to European Clinical Trials Database record.
    • 11 Oct 2011 Planned end date changed from 1 Feb 2010 to 1 May 2011 as reported by ClinicalTrials.gov.
    • 16 Jun 2011 Results presented at the 11th International Conference on Malignant Lymphoma (ICML).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top